BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 33417267)

  • 1. miR-218 contributes to drug resistance in multiple myeloma via targeting LRRC28.
    Chen H; Cao W; Chen J; Liu D; Zhou L; Du F; Zhu F
    J Cell Biochem; 2021 Apr; 122(3-4):305-314. PubMed ID: 33417267
    [TBL] [Abstract][Full Text] [Related]  

  • 2. miR-520g and miR-520h overcome bortezomib resistance in multiple myeloma via suppressing APE1.
    Yuan X; Ma R; Yang S; Jiang L; Wang Z; Zhu Z; Li H
    Cell Cycle; 2019 Jul; 18(14):1660-1669. PubMed ID: 31204563
    [No Abstract]   [Full Text] [Related]  

  • 3. hsa-miR-631 resensitizes bortezomib-resistant multiple myeloma cell lines by inhibiting UbcH10.
    Xi H; Li L; Du J; An R; Fan R; Lu J; Wu YX; Wu SX; Hou J; Zhao LM
    Oncol Rep; 2017 Feb; 37(2):961-968. PubMed ID: 28000886
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CircRNA ITCH increases bortezomib sensitivity through regulating the miR-615-3p/PRKCD axis in multiple myeloma.
    Liu J; Du F; Chen C; Li D; Chen Y; Xiao X; Hou X
    Life Sci; 2020 Dec; 262():118506. PubMed ID: 33031827
    [TBL] [Abstract][Full Text] [Related]  

  • 5. LncRNA PRAL is closely related to clinical prognosis of multiple myeloma and the bortezomib sensitivity.
    Xiao G; Li Y; Wang Y; Zhao B; Zou Z; Hou S; Jia X; Liu X; Yao Y; Wan J; Xiong H
    Exp Cell Res; 2018 Sep; 370(2):254-263. PubMed ID: 29944867
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exosomal mRNAs and lncRNAs involved in multiple myeloma resistance to bortezomib.
    Tang JX; Chen Q; Li Q; He YH; Xiao D
    Cell Biol Int; 2021 May; 45(5):965-975. PubMed ID: 33372728
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ectopic expression of BIRC5-targeting miR-101-3p overcomes bone marrow stroma-mediated drug resistance in multiple myeloma cells.
    Abdi J; Rastgoo N; Chen Y; Chen GA; Chang H
    BMC Cancer; 2019 Oct; 19(1):975. PubMed ID: 31638931
    [TBL] [Abstract][Full Text] [Related]  

  • 8. LncRNA H19 overexpression induces bortezomib resistance in multiple myeloma by targeting MCL-1 via miR-29b-3p.
    Pan Y; Zhang Y; Liu W; Huang Y; Shen X; Jing R; Pu J; Wang X; Ju S; Cong H; Chen H
    Cell Death Dis; 2019 Feb; 10(2):106. PubMed ID: 30728351
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MiR-197-3p reduces bortezomib resistance in multiple myeloma by inhibiting IL-6 expression in a MEAF6-dependent manner.
    Liu Y; Cheng P; Zhao W; Zhu L; Sui J; Dai Y; Lai Y
    Leuk Res; 2022 Mar; 114():106785. PubMed ID: 35074616
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MicroRNA-324-5p regulates stemness, pathogenesis and sensitivity to bortezomib in multiple myeloma cells by targeting hedgehog signaling.
    Tang B; Xu A; Xu J; Huang H; Chen L; Su Y; Zhang L; Li J; Fan F; Deng J; Tang L; Sun C; Hu Y
    Int J Cancer; 2018 Jan; 142(1):109-120. PubMed ID: 28905994
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MicroRNA-497 inhibits multiple myeloma growth and increases susceptibility to bortezomib by targeting Bcl-2.
    Tian F; Zhan Y; Zhu W; Li J; Tang M; Chen X; Jiang J
    Int J Mol Med; 2019 Feb; 43(2):1058-1066. PubMed ID: 30535471
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lnc NEAT1/miR-29b-3p/Sp1 form a positive feedback loop and modulate bortezomib resistance in human multiple myeloma cells.
    Che F; Ye X; Wang Y; Ma S; Wang X
    Eur J Pharmacol; 2021 Jan; 891():173752. PubMed ID: 33253679
    [TBL] [Abstract][Full Text] [Related]  

  • 13. miR-200bc/429 cluster modulates multidrug resistance of human cancer cell lines by targeting BCL2 and XIAP.
    Zhu W; Xu H; Zhu D; Zhi H; Wang T; Wang J; Jiang B; Shu Y; Liu P
    Cancer Chemother Pharmacol; 2012 Mar; 69(3):723-31. PubMed ID: 21993663
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MiR-222 and miR-29a contribute to the drug-resistance of breast cancer cells.
    Zhong S; Li W; Chen Z; Xu J; Zhao J
    Gene; 2013 Nov; 531(1):8-14. PubMed ID: 23994196
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Study on the Association Between miRNA-202 Expression and Drug Sensitivity in Multiple Myeloma Cells.
    Shen X; Guo Y; Qi J; Shi W; Wu X; Ni H; Ju S
    Pathol Oncol Res; 2016 Jul; 22(3):531-9. PubMed ID: 26689580
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Downregulation of miR-130a contributes to cisplatin resistance in ovarian cancer cells by targeting X-linked inhibitor of apoptosis (XIAP) directly.
    Zhang X; Huang L; Zhao Y; Tan W
    Acta Biochim Biophys Sin (Shanghai); 2013 Dec; 45(12):995-1001. PubMed ID: 24145606
    [TBL] [Abstract][Full Text] [Related]  

  • 17. miR-218 targets survivin and regulates resistance to chemotherapeutics in breast cancer.
    Hu Y; Xu K; Yagüe E
    Breast Cancer Res Treat; 2015 Jun; 151(2):269-80. PubMed ID: 25900794
    [TBL] [Abstract][Full Text] [Related]  

  • 18. miR-15b and miR-16 modulate multidrug resistance by targeting BCL2 in human gastric cancer cells.
    Xia L; Zhang D; Du R; Pan Y; Zhao L; Sun S; Hong L; Liu J; Fan D
    Int J Cancer; 2008 Jul; 123(2):372-379. PubMed ID: 18449891
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potential role of exosome-associated microRNA panels and in vivo environment to predict drug resistance for patients with multiple myeloma.
    Zhang L; Pan L; Xiang B; Zhu H; Wu Y; Chen M; Guan P; Zou X; Valencia CA; Dong B; Li J; Xie L; Ma H; Wang F; Dong T; Shuai X; Niu T; Liu T
    Oncotarget; 2016 May; 7(21):30876-91. PubMed ID: 27129167
    [TBL] [Abstract][Full Text] [Related]  

  • 20. miR-20a mediates temozolomide-resistance in glioblastoma cells via negatively regulating LRIG1 expression.
    Wei J; Qi X; Zhan Q; Zhou D; Yan Q; Wang Y; Mo L; Wan Y; Xie D; Xie J; Yang S
    Biomed Pharmacother; 2015 Apr; 71():112-8. PubMed ID: 25960225
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.